Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Other Operating Expenses: 2009-2025

Historic Other Operating Expenses for Madrigal Pharmaceuticals (MDGL) over the last 2 years, with Sep 2025 value amounting to $18.1 million.

  • Madrigal Pharmaceuticals' Other Operating Expenses rose 742.10% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.1 million, marking a year-over-year increase of 1222.73%. This contributed to the annual value of $6.2 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Other Operating Expenses of $18.1 million as of Q3 2025, which was up 99.91% from $9.1 million recorded in Q2 2025.
  • In the past 5 years, Madrigal Pharmaceuticals' Other Operating Expenses ranged from a high of $18.1 million in Q3 2025 and a low of $636,000 during Q2 2024.
  • Moreover, its 2-year median value for Other Operating Expenses was $4.0 million (2024), whereas its average is $6.3 million.
  • Data for Madrigal Pharmaceuticals' Other Operating Expenses shows a peak YoY surged of 1,325.31% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Madrigal Pharmaceuticals' Other Operating Expenses stood at $3.4 million in 2024, then surged by 742.10% to $18.1 million in 2025.
  • Its Other Operating Expenses was $18.1 million in Q3 2025, compared to $9.1 million in Q2 2025 and $4.5 million in Q1 2025.